Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review

Pang, A., Carbini, M., Maki, R. G. (July 2016) Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. JAMA Oncol, 2 (7). pp. 941-7. ISSN 2374-2437

URL: https://www.ncbi.nlm.nih.gov/pubmed/27148906
DOI: 10.1001/jamaoncol.2016.0241

Abstract

IMPORTANCE: Immune checkpoint inhibitors have shown promising results in several cancers and are now put to the test in sarcomas. This brief summary presents data regarding the previously approved and newer agents for more common sarcomas and focuses on specific sarcoma histologic subtypes or novel approaches for which there is particular optimism. Approaches involving epigenetic agents, metabolic therapy, and modulators of the tumor microenvironment represent other ways the field of sarcoma medical oncology will progress in 2016 and beyond. OBSERVATIONS: A recent series of successful randomized trials provides new systemic therapy options for patients with metastatic soft-tissue sarcomas in the United States, after a gap of more than 10 years in which no new drugs were approved. The agents with most recent approval include pazopanib, trabectedin, and eribulin. As a sign that progress is not linear, 2 cousins of ifosfamide failed to show benefit in phase 3 trials, despite prior positive results of randomized phase 2 trials. CONCLUSIONS AND RELEVANCE: The biological features of each sarcoma subtype are associated with specific sensitivity patterns to chemotherapy, and despite their rarity, future trials will need to emphasize specific histologic subtypes (many with well-defined genetic alterations) to best fit diagnosis to therapy.

Item Type: Paper
Uncontrolled Keywords: Adult Antineoplastic Agents/adverse effects/*therapeutic use Dioxoles/adverse effects/therapeutic use Furans/adverse effects/therapeutic use Humans Ketones/adverse effects/therapeutic use Pyrimidines/adverse effects/therapeutic use Randomized Controlled Trials as Topic Sarcoma/*drug therapy/pathology Sulfonamides/adverse effects/therapeutic use Tetrahydroisoquinolines/adverse effects/therapeutic use Tumor Microenvironment/*drug effects
Subjects: diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL Cancer Center Program > Signal Transduction
CSHL labs > Maki lab
Depositing User: Matt Covey
Date: 1 July 2016
Date Deposited: 05 Mar 2018 20:43
Last Modified: 05 Mar 2018 20:43
Related URLs:
URI: http://repository.cshl.edu/id/eprint/36175

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving